secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0000950170-25-053953
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed doses first patient in Phase 3 Emerge study of MM120 ODT for MDD
------------------------------------------------------------------------

- First patient dosed in Phase 3 Emerge study evaluating MM120 ODT 100 µg vs placebo in major depressive disorder.
- Primary endpoint: change from baseline in MADRS score at Week 6; ~140 participants expected in U.S.
- Topline data from the 12-week double-blind period anticipated in second half of 2026.
- Emerge is the third Phase 3 study of MM120 ODT; Voyage and Panorama studies in GAD are already underway.
- Phase 2b GAD study showed clinically and statistically significant MADRS improvements after single 100 µg dose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017025053953/0000950170-25-053953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017025053953/mnmd-20250415.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-053953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer